InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
BioAddict Free
06/03/20 10:43 AM
profile icon
BioAddict Free
06/02/20 5:23 PM
profile icon
ClayTrader Free
06/02/20 4:53 PM
profile icon
Pt3 Free
06/02/20 4:25 PM
profile icon
Walker Grandfathered
06/02/20 2:48 PM
profile icon
hardcore PremiumMember
06/02/20 10:14 AM
profile icon
Liquid1974 Free
06/02/20 9:43 AM
profile icon
GKG Free
06/02/20 8:19 AM
profile icon
crudeoil24 PremiumMember
06/02/20 7:43 AM
profile icon
Tommy321 Free
06/01/20 5:08 PM
profile icon
Walker Grandfathered
06/01/20 5:03 PM
profile icon
Logic1 Free
05/29/20 6:45 PM
profile icon
casenumber Free
05/28/20 11:23 PM
profile icon
makingbiigdough Free
05/27/20 12:04 PM
profile icon
Walker Grandfathered
05/27/20 10:03 AM
profile icon
makingbiigdough Free
05/26/20 12:08 PM
profile icon
makingbiigdough Free
05/22/20 12:23 PM
profile icon
Walker Grandfathered
05/21/20 7:26 AM
profile icon
Walker Grandfathered
05/20/20 5:17 PM
profile icon
Walker Grandfathered
05/20/20 2:03 PM
profile icon
Walker Grandfathered
05/20/20 9:10 AM
profile icon
makingbiigdough Free
05/07/20 10:06 AM
profile icon
Rogerthat1 Free
05/01/20 7:56 AM
profile icon
Rogerthat1 Free
05/01/20 12:54 AM
profile icon
Warchest Free
04/15/20 2:31 PM
profile icon
Rogerthat1 Free
04/05/20 7:23 PM
profile icon
makingbiigdough Free
04/01/20 11:40 AM
profile icon
makingbiigdough Free
03/31/20 10:26 AM
profile icon
Rogerthat1 Free
03/31/20 8:01 AM
profile icon
makingbiigdough Free
03/30/20 11:32 PM
profile icon
Rogerthat1 Free
03/30/20 9:52 PM
profile icon
Rogerthat1 Free
03/30/20 9:49 PM

Tenax Therapeutics Inc (TENX) RSS Feed

Followers
123
Posters
518
Posts (Today)
0
Posts (Total)
8299
Created
05/19/03
Type
Free
Moderators


Tenax Therapeutics Corporate update - November 2016
http://cdn.irdirect.net/IR/942/1803/TENX%20Overview%20--%20Nov%202016%20.pdf


Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass (LEVO-CTS)
https://clinicaltrials.gov/ct2/show?term=tenax&rank=2

Experimental: Levosimendan
levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours

Placebo Comparator: Placebo
placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
Criteria

Inclusion Criteria:

  • Documented LVEF ≤35% measured by ventriculogram, echocardiogram (ECHO), nuclear scan, or MRI within 60 days before surgery.
    Scheduled or urgent 1) CABG surgery, 2)CABG with aortic valve surgery, 3) CABG with mitral valve surgery, or 4) mitral valve surgery with or without other valves
    Surgery will employ CPB pump
    Signed (by the subjects or their legally acceptable representatives) informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

  • Restrictive or obstructive cardiomyopathy, constrictive pericarditis, restrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent on venous return.
    Evidence of systemic bacterial, systemic fungal, or viral infection within 72 hours before surgery.
    Dialysis at randomization (either hemodialysis, peritoneal dialysis, continuous venovenous hemofiltration, or ultrafilitration).
    Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2.
    Weight ≥ 170 kg.
    Patients whose SBP cannot be managed to ensure SBP > 90 mmHg at initiation of study drug.
    Heart rate ≥ 120 bpm, persistent for at least 10 minutes screening and unresponsive to treatment.
    Hemoglobin < 80 g/L.
    Serum potassium < 3.5 mmol/L and > 5.5 mmol/L at baseline.
    A history of Torsades de Pointes.
    Mechanical assist device (IABP, LVAD, ECMO) in the patient at the start of surgery or pre-planned to be inserted during surgery before coming off CPB.
    Patients with aortal femoral occlusive disease that would prohibit use of IABP unless VAD or ECMO not available.
    Liver dysfunction Child Pugh Class B or C
    Patients having severely compromised immune function
    Pregnant, suspected to be pregnant, or breast-feeding.
    Received an experimental drug or used an experimental medical device in previous 30 days.
    Known allergic reaction or sensitivity to Levosimendan or excipients.
    Received commercial Levosimendan within 30 days before the planned start of study drug.
    Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.


https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0060007


Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion


http://www.internationaljournalofcardiology.com/article/S0167-5273%2815%2900149-7/pdf

 
New Post